Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - Akero Therapeutics, Inc. | akro-20201231ex3124af347.htm |
| EX-31.1 - EX-31.1 - Akero Therapeutics, Inc. | akro-20201231ex3113fca1e.htm |
| EX-23.1 - EX-23.1 - Akero Therapeutics, Inc. | akro-20201231ex231dba57d.htm |
| EX-21.1 - EX-21.1 - Akero Therapeutics, Inc. | akro-20201231ex211384978.htm |
| 10-K - 10-K - Akero Therapeutics, Inc. | akro-20201231x10k.htm |
EXHIBIT 32.1*
Certification of Principal Executive Officer and Principal Financial Officer
Pursuant to 18 U.S.C. Section 1350
(as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002)
In connection with the Annual Report of Akero Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2020 (the “Report”), the undersigned hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of their knowledge:
1. | the Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and |
2. | the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Dated: March 16, 2021 | /s/ ANDREW CHENG |
| Andrew Cheng, M.D., Ph.D. |
| President and Chief Executive Officer |
| (Principal Executive Officer) |
Dated: March 16, 2021 | /s/ WILLIAM WHITE |
| William White |
| Executive Vice President, Chief Financial Officer and Head of Corporate Development |
| (Principal Financial and Accounting Officer) |
* This certification shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liability of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934.
1